Postmarketing surveillance of the safety and effectiveness of etanercept in Japan

Journal of Rheumatology

Volumn 36, Issue 5, 2009, Pages 898-906

  Koike, Takao ^b   Harigai, Masayoshi ^c   Inokuma, Shigeko ^d   Inoue, Kazuhiko ^e   Ishiguro, Naoki ^f   Ryu, Junnosuke ^g   Takeuchi, Tsutomu ^h   Tanaka, Yoshiya ⁱ   Yamanaka, Hisashi ^j   Fujii, Koichi ^k   Freundlich, Bruce ^a   Suzukawa, Michio ^k  

^a PFIZER INC   (United States)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h SAITAMA MEDICAL UNIVERSITY   (Japan)

ⁱ UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^j TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^k Wyeth KK Medical Affairs   (Japan)

more..

Author keywords

Efficacy; Etanercept; Japan; Postmarketing surveillance; Rheumatoid arthritis; Safety

Indexed keywords

BUCILLAMINE; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL ARTHRITIS; CELLULITIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG SAFETY; ERYTHEMA; FEMALE; FEMUR NECK FRACTURE; FEVER; HERPES ZOSTER; HUMAN; INJECTION SITE REACTION; INTERSTITIAL LUNG DISEASE; JAPAN; LIVER FUNCTION; LUNG TUBERCULOSIS; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRURITUS; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPSIS; SIDE EFFECT; TREATMENT RESPONSE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; DRUG SURVEILLANCE PROGRAM; MIDDLE AGED; STATISTICS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; JAPAN; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67449102437     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080791     Document Type: Article

References (26)

1. U.S. Food and Drug Administration. MEDWatch Program. [Internet. Accessed February 6, 2009.] Available from: http://www.fda.gov/cder/handbook/medwatch.htm
2. Carleton B, Foerster V, Warren L, Smith MA. Post-marketing pharmaco-surveillance in Canada. Health Canada website. [Internet. Accessed February 6, 2009.] Available from: http://www.hc-sc.gc.ca/hcs-sss/alt-formats/ hpb-dgps/pdf/pharma/ref-can-e.pdf
3. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis 2002;61 Suppl 2:ii2-ii7.
4. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNF-alpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005;44:157-63.
5. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
6. Innovations Report. Half of patients with active early rheumatoid arthritis achieved clinical remission. Innovations Report website [Internet. Accessed February 6, 2009.] Available from: http://www.innovationsreport.com/ html/reports/medicine-health/report-95903.html
7. Japan College of Rheumatology. Introducing Japan College of Rheumatology (JCR). Japan College of Rheumatology website [Internet. Accessed February 6, 2009.] Available from: http://www.ryumachi-jp.com/english/index.html
8. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
9. Northrup Grumman Corporation. MedDRA and the MSSO. Northrup Grumman Corporation website [Internet. Accessed February 6, 2009.] Available from: http://www.meddramsso.com/MSSOWeb/index.htm
10. ICH Steering Committee. ICH Harmonised Tripartite Guideline. Clinical safety data management: definitions and standards for expedited reporting. Pharmaceuticals and Medical Devices Agency website [Internet. Accessed February 6, 2009.] Available from: http://www.pmda.go.jp/ich/e/e2a-95-3-20e.pdf
11. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
12. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
13. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-46.
14. Bernatsky S, Feldman D, Shrier I, et al. Care pathways in early rheumatoid arthritis. Can Fam Physician 2006;52:1444-5.
15. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: Comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2007;124-34.
16. van Riel PL, Taggart AJ, Sany J, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: The ADORE study. Ann Rheum Dis 2006;65:1478-83.
17. Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:353-63.
18. Klareskog L, van der Heijde D, De Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
19. Hamdi H, Mariette X, Godot V, et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006;8:R114.
20. Botha T, Ryffel B. Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol 2003;171:3110-8.
21. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006;20:757-90.
22. Long R, Gardam M. Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ 2003;168:1153-6.
23. World Health Organization. Global tuberculosis control: surveillance, planning, financing: WHO Report 2007. World Health Organization website. [Internet. Accessed February 6, 2009.] Available from: http://www.who.int/tb/en/
24. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
25. Jundt JW, Browne BA, Fiocco GP, Steele AD, Mock D. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993;20:1845-9.
26. van der Heijde D, Da Silva JC, Dougados M, et al. Once-weekly 50-mg dosing of Etanercept (Enbrel®) is as effective as 25-mg twice-weekly dosing in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:1572-7.